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Abstract
Background: Juvenile idiopathic arthritis associated uveitis (JIA-U) is the most common extra-articular manifestation
of juvenile idiopathic arthritis (JIA) and carries considerable risk to vision. The aim of this systematic review was to
synthesise evidence of environmental risk factors for JIA-U and identify risk factors which may be modifiable or
used to stratify JIA patients.
Methods: This systematic review was carried out in accordance with PRISMA guidelines. Four online databases - Cumulative
Index of Nursing and Allied Health Literature, Web of Science, MEDLINE and Embase - were searched from database
inception to 12th August 2020. Identified studies were screened by two independent reviewers against pre-defined inclusion
and exclusion criteria. Data was extracted from all primary studies meeting inclusion criteria and independently checked.
Results:We identified three studies from 895 unique records which met the inclusion criteria, each examining a different
environmental risk factor. This systematic review includes 973, predominantly female, participants with JIA across these three
studies. The use of allergy medication or documentation of “allergy”/“allergic” in the medical records was associated with an
increased risk of JIA-U in all models presented. Vitamin D sufficiency was associated with reduced risk of JIA-U. There was
insufficient evidence to support an association between seasonality and JIA-U.
Conclusions: This review identifies a potential role for allergy and vitamin D in JIA-U. It also illustrates the paucity of data
regarding environmental risk factors for JIA-U and highlights the need for further research to both identify additional risk
factors and replicate existing findings.
Keywords: Juvenile idiopathic arthritis, Uveitis, Risk factors, Environment, Vitamin D, Season, Allergy
Background
Juvenile idiopathic arthritis (JIA) is the most common
rheumatic condition of childhood and juvenile idiopathic
arthritis associated uveitis (JIA-U) is the most common as-
sociated extra-articular manifestation. The estimated preva-
lence of JIA-U in JIA patients is 11–38% [1, 2]. However,
prevalence varies by JIA subtype with estimates as high as
47% in oligoarticular JIA [3]. JIA-U is often asymptomatic
but carries considerable risk to vision thus children with
JIA undergo regular ophthalmic screening [4]. Guidelines
for frequency and duration of JIA-U screening are based on
existing clinical risk factors of gender, JIA subtype, age of
JIA onset, and anti-nuclear antibody (ANA) and HLA-B27
status. However these lack specificity and children may still
develop uveitis between screening visits [5].
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JIA-U is considered to be a heterogenous disease,
driven by both genetic and environmental factors. There
has been increasing literature regarding genetic influ-
ences on JIA-U susceptibility [6] and the first genome
wide association study of JIA-U has recently been pub-
lished [7]. It has previously be noted that evidence of ex-
ternal (environmental) triggers for JIA-U is limited and
environmental risk factors for all cause uveitis have been
summarised [8]. However, the identification of specific
risk factors for JIA-U will assist in improving the JIA-U
screening programmes as well as potentially redefining
treatment strategies for patients based on their individ-
ual risk profile. Thus, the aim of this systematic review
is to identify environmental risk factors associated with
JIA-U incidence which may either be modifiable or assist
in risk stratification of JIA patients. To our knowledge
this is the first systematic review examining environmen-
tal risk factors for JIA-U.
Methods
This study follows guidance from the Preferred Report-
ing Items for Systematic Reviews and Meta-analyses
(PRISMA) statement [9]. The protocol for this system-
atic review was pre-registered on PROSPERO (ID:




Literature searching of online bibliographic databases
were carried out in order to identify literature on environ-
mental risk factors associated with JIA-U. Expert advice
from a database searching specialist was sought prior to
designing the search strategy. Each search was carried out
in four databases; MEDLINE and Embase via Ovid, Web
of Science (WOS) via Clarivate Analytics and Cumulative
Index of Nursing and Allied Health Literature (CINAHL)
via EBSCOhost. Searches included literature from data-
base inception until 12th August 2020. Table 1 shows the
search strategy that was used for MEDLINE; the syntax
was amended for use in other databases. All searches were
limited to studies in English only.
Study selection
References (including abstracts where available) were
downloaded into Endnote X9 (Clarivate Analytics) and
duplicates were removed. All unique references were
uploaded to Rayyan [11] and underwent title and abstracts
screening by two independent reviewers (SC and KM/HC)
against the inclusion and exclusion criteria listed in
Table 2. The full texts of potentially relevant studies iden-
tified during title and abstract screening were retrieved.
These articles were again independently screened by two
reviewers (SC and KM/HC). Bibliographies of review
articles were also hand-searched to identify other poten-
tially relevant studies and expert advice was sought from
AR regarding key studies which may not have been cap-
tured within our searches. Any discrepancies during
screening were resolved by discussion and/or involvement
of the third reviewer (AR). Where a study was felt to be
highly relevant but key inclusion/exclusion criteria were
not reported, study authors were contacted prior to a final
decision being made.
Data extraction
A data extraction form was created and piloted in
Microsoft Excel by SC and KM. Data was extracted from
each eligible study by SC and independently checked by
KM/HC. Data extraction consisted of:
– First author
– Study title
– Year of publication
– Study country
– Participant demographic characteristics
– Sample size
– Diagnostic criteria used
– Length of follow-up
– Outcomes
– Event rates for unexposed/exposed cases and
controls
– Risk factors listed in univariate and multivariate
analyses
– Covariates adjusted for in analysis
– Source of risk factor ascertainment
– JIA and JIA-U subtypes included
– Newcastle-Ottawa scale scores
For consistency between studies, the extracted sample
size was the sample size of the largest analysis under-
taken within a study. All data is presented as odds ratio
and 95% confidence intervals where possible.
Risk of bias (quality) assessment
The methodological quality and risk of bias of included
studies was assessed using the Newcastle-Ottawa Scale
(NOS) for case-control and cohort studies [12]. Studies
were independently scored by SC and KM/HC and any
discrepancies were resolved by discussion and/or involve-
ment of a third reviewer (AR). A risk of biases table was
created summarising the star rating of included studies
(maximum score of 9 stars reflecting the highest quality).
Data synthesis
None of the included studies examined overlapping risk
factors, thus there was no data suitable for the quantita-
tive meta-analysis. Therefore, as specified in our proto-
col, the data within this systematic review is synthesised
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in narrative form. The principal summary measure for
this systematic review is unadjusted and adjusted odds
ratio. Where this was not reported by a study, or was
not possible to derive from the raw data presented
within a study, we used the study reported summary
measure for data synthesis.
Results
Study selection
Searches of CINAHL, Embase, MEDLINE and WOS on
12th August 2020 identified 1314 JIA-U studies. After
collation, 419 studies were identified as duplicates by
Endnote X9. The majority of studies were excluded
during title and abstract screening. In total, 67 studies
were assessed in full and of these, three studies met the
inclusion criteria listed in Table 2. The flowchart for se-
lection of included studies and specific reasons for ex-
clusion is shown in Fig. 1.
Characteristics of included studies
The characteristics of the three included studies are
shown in Table 3. All studies were retrospective cohort
studies. Due to publication date and country of origin,
the studies are presumed to encompass non-overlapping
samples thus this systematic review includes a total sam-
ple size of 973 participants. All studies reported female
predominance to JIA-U within the JIA population. Cole
et al [14] and Sengler et al [15] reported statistically sig-
nificant differences in the mean age of JIA onset be-
tween JIA-U cases and controls; patients who developed
JIA-U had younger age of JIA onset. Zulian et al [13]
also reported a lower mean age of JIA onset in patient
who developed mild JIA-U however this did not reach
statistical significance. All three studies utilised different
JIA and JIA-U diagnostic criteria and included different
JIA subtypes.
Quality assessment and risk of bias
The NOS score of the included studies ranged from five
to seven, with the full breakdown of NOS scores shown
in Table 4. All studies lost points for the length of par-
ticipant follow-up.
Environmental risk factors
Three environmental risk factors from three studies
were examined – seasonality, allergy and vitamin D, see
Table 5. Of these, only seasonality was reported in an
unadjusted model; unadjusted estimates were not re-
ported for allergy and vitamin D, nor was sufficient raw
data provided in the studies to derive this estimate.
Zulian et al [13] reported winter to be associated with
an increased risk of JIA-U, autumn and spring to be as-
sociated with a decreased risk of JIA-U and summer to
show no association with JIA-U. The confidence interval
around these estimates were not reported, nor was suffi-
cient event rate data available to derive these. In all
cases, the p value was > 0.05 (exact values not reported),
providing insufficient evidence to support an association
between seasonality and JIA.
Both allergy and vitamin D were examined in an ad-
justed model. Cole et al [14] reported the association be-
tween allergy and JIA-U by examining the
documentation of “allergy” or “allergic” within the clin-
ical records, and the documented use of allergy medica-
tion. Bivariate analysis demonstrated that “allergy” or
“allergic” in the medical records, and the use of allergy
medications were all associated with an increased risk of
Table 1 Search strategy for MEDLINE by OVID (syntax amended
for use in other databases)

























26 (season* adj3 birth).tw
27 smok*.tw
28 virus.tw
29 1 or 2
30 3 or 4 or 5 or 6 or 7 or 8 or 9
31 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
or 22 or 23 or 24 or 25 or 26 or 27 or 28
32 29 and 30 and 31
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Table 2 Inclusion and exclusion criteria for studies




Study type Systematic review









Patients with juvenile idiopathic arthritis associated uveitis (JIA-U), diagnosed using any
recognised uveitis diagnostic criteria [e.g. International Uveitis Study Group (IUSG),
Standardised Uveitis Nomenclature (SUN), International Classification of Diseases (ICD)]
who also meet diagnostic criteria for juvenile idiopathic arthritis (JIA), diagnosed using
any recognised criteria [e.g. American College of Rheumatology (ACR), EULAR,,
International League of Associations for Rheumatology (ILAR), ICD]
PLUS
Onset of disease at or before 16 years of age
Adults (defined as age > 16 yrs)
Study
comparator




Environmental risk factors (including patient, familial and perinatal) Non-environmental risk factors (e.g. genetic,
ethnic/racial, familial aggregation)
Fig. 1 PRISMA flow diagram of study selection
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JIA-U (Table 5). The use of allergy medication was also
reported to be associated with increased risk of JIA-U
(OR 2.54, 95% CI 1.22–5.40) in a model adjusted for
race, gender, age, oligoarticular subtype, ANA, rheuma-
toid factor (RF) and psoriasis. Sengler et al [15] investi-
gated the risk of JIA-U according to vitamin D status.
They reported the risk of JIA-U to be inversely corre-
lated with mean vitamin D level in a multivariable model
(HR 0.95, 95% CI 0.91–0.99) adjusted for methotrexate
use and existing uveitis risk factors (including at JIA on-
set, female sex, oligoarticular JIA, and ANA positivity).
This association persisted when the study population
was restricted to those participants for whom vitamin D
status was measured prior to JIA-U onset.
Discussion
The literature search strategy was designed to capture
environmental risk factors for JIA-U in the broadest
sense and identify all relevant literature regarding JIA-U
risk. Nevertheless, the identification of only three studies
highlights the unmet research need in this area.
The demographic characteristics of the included stud-
ies illustrate that they are representative of the JIA com-
munity; JIA-U is reported to be more common in
younger, female JIA patients as is seen here. The NOS
scores of the studies suggest the studies are of generally
of good quality. However, all studies lost points for fail-
ing to meet adequate follow-up; length of follow up was
reported to be 3 years by Sengler et al and a minimum
of 2 years by Zulian et al, but was not reported in the
study by Cole et al. The natural history of JIA-U sug-
gests that 90% of JIA patients develop JIA-U within the
first 4 years after JIA diagnosis [16, 17]. Thus, risk factor
studies in JIA-U should ideally follow up participants for
at least this period of time. These findings are likely to
reflect the challenges of performing robust studies in
rare diseases where patient cohorts are small and where
appropriate datasets to identify and analyse risk factors
robustly may be lacking or limited.
JIA-U is generally considered to be a complex disease,
influenced by both genetic and environmental risk fac-
tors. The use of broad literature search terms used in
this systematic review captured 692 de-duplicated re-
cords yet identified only three studies which met the in-
clusion criteria. Correspondingly we only identified three
environmental risk factors which had been examined
with regards to JIA-U incidence, none of which over-
lapped sufficiently to enable statistical comparison.
Whilst the primary limitation to performing meta-
analysis was lack of replicated risk factors, it should be
noted that the included studies used different criteria to
ascertain JIA cohorts and define JIA-U status. A number
of different criteria have been defined and amended to
diagnose JIA over the past 50 years [18] alongside on-
going revisions of the ICD codes. Furthermore, uveitis
criteria have also evolved over this time [19]. These fac-
tors make the synthesis of historic data challenging and
should be considered in planning future studies.
There is increasing recognition of the seasonal vari-
ation in both the incidence and disease activity of a
number of autoimmune diseases. However, the influence
of seasonality on autoimmunity is likely complex and
multifactorial. Seasonal variation is observed with a
number of factors such as infections, ultraviolet light
Table 3 Characteristics of included studies. *Demographic data for this study was stratified by uveitis severity. ICD, International
Classification of Diseases, ILAR, International League of Associations for Rheumatology; IUSG, International Uveitis Study Group; JIA,
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exposure, vitamin D and melatonin [20]. Winter is asso-
ciated with viral respiratory pathogens, spring is associ-
ated with bacterial respiratory pathogens such as
Mycoplasma pneumoniae [21] and late summer/early
autumn is associated with increased prevalence of viral
pathogens such as Enterovirus [22]. Seasonal viral infec-
tions are postulated to contribute to autoimmunity via
mechanisms such as molecular mimicry, epitope spread-
ing and bystander activation [23]. In addition, seasonal
sunlight exposure markedly influences vitamin D levels
[24], which peak in the summer/autumn and reach a
nadir in the winter. Vitamin D has a number of effects
on immune function [25] though evidence for hypovita-
minosis D as a risk factor for autoimmune disease inci-
dence, with the exception of multiple sclerosis, is
limited. Nevertheless the finding of an association be-
tween vitamin D and JIA-U is also supported by a study
examining the role of vitamin D in non-infectious uveitis
in adults (sample size 3348) which found a 21% reduc-
tion in uveitis risk with normal versus low vitamin D
levels (≤20 ng/mL) [26]. Whilst this uveitis cohort does
not specifically examine JIA-U, it includes participants
with other T-cell driven uveitides. Furthermore, the con-
cordant directions of effect seen in the association be-
tween seasonality and JIA-U add strength to the
association with vitamin D; Zulian et al [13] found au-
tumn to be associated with decreased risk of JIA-U and
winter to be associated with an increased risk of JIA-U
(albeit in univariate analysis with a p-value > 0.05) and
Sengler et al [15] reported vitamin D sufficiency to be
significantly associated with decreased risk of JIA-U.
There are a number of possible reasons for these find-
ings; hypovitaminosis D may itself be a risk factor for
JIA-U, it may be a marker of another seasonal exposure,
or several seasonal factors may act in combination (e.g.
hypovitaminosis D and an infectious agent). Addition-
ally, these associations may be spurious findings given
the limited data seen here. Further studies to corrobor-
ate and delineate these associations, and allow meta-
analysis of the results are warranted. However, such
studies are challenging; the asymptomatic nature and in-
sidious onset of JIA-U means the vitamin D level or sea-
son at diagnosis may not reflect the vitamin D level or
season at JIA-U onset. This temporality needs consider-
ation when designing future studies, which should
ideally take place in the context of regular and frequent
ophthalmic screening.
Traditionally allergy and autoimmunity were felt to
represent different facets of a perturbed immune system
under the Th1/Th2 paradigm – with autoimmune dis-
eases presenting in those with a more T helper cell type
1 (Th1) predisposition and allergies presenting in those
with a more T helper cell type 2 (Th2) predisposition
[27, 28]. However, this paradigm has been challenged in
more recent years with the discovery of Th17 cells [29].
Recent data has been shown that rather than being pro-
tective, patients with allergic and atopic conditions are
at increased risk of developing autoimmunity [30]. We
found limited data on the association between allergy
and JIA-U, however the direction and magnitude of this
association is comparable with estimates of other al-
lergy/atopy/autoimmune associations reported by
Krishna et al [30]. Given the immunopathogenic basis of
allergic/atopic and autoimmune diseases, it is difficult to
ascertain whether associations between these two disease
types are evidence of a causal relationship (and in which
direction) or whether this association is a correlation
due to, for example, underlying perturbation of immune
function. Nevertheless, given the increasingly recognised
association between autoimmune and allergic traits,
Table 5 Risk factors associated with JIA-U. areported point estimate, bconfidence intervals not reported, p-value > 0.05, cadjusted
for race and gender, dadjusted for race, gender, age, oligo subtype, ANA, RF, psoriasis, ereported as HR, fadjusted for MTX and uveitis
risk factors (age of JIA onset, female sex, oligoarticular JIA and ANA positivity), gwhen analysed by patients who were sampled prior
to uveitis diagnosis the results were HR 0.95, 95% CI 0.92–1.00. ANA, anti-nuclear antibody; CI, Confidence interval; HR, hazard ratio;
MTX, methotrexate; NR, not reported; OR, odds ratio; RF, rheumatoid factor; 25(OH) D, 25-hydroxyvitamin D
Study ID Risk
factor








Seasonality Autumn 0.85a,b NR NR
Summer 1.00a,b NR NR
Winter 1.39a,b NR NR
Spring 0.96a,b NR NR
Cole, 2013 [14] Allergy “Allergy” in clinical notes NR 2.14 (1.08–4.27)c NR
“Allergic” in clinical notes NR 2.68 (1.34–5.55)c NR
Any allergy medication NR 2.92 (1.47–5.91)c 2.54 (1.22–5.4)d
Sengler, 2018
[15]
Vitamin D 1 ng/mL increase in 25(OH) D level > 22.1
ng/mL
NR NR 0.95 (0.91–0.99)e,f,g
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further studies and resultant meta-analyses in JIA-U
may provide support for clinicians to highlight JIA pa-
tients with increased JIA-U risk based on their allergy
status.
The reasons for the high incidence of uveitis in pa-
tients with JIA are poorly understood. Whilst identifica-
tion and examination of the environmental risk factors
overlapping JIA and JIA-U is outside of the scope of this
study, a recent review of environmental determinants of
JIA [31] reported unclear associations between JIA and
the risk factors described here. This study provides an
important step in identifying shared and distinct envir-
onmental influences on JIA and JIA-U, understanding
their role in the aetiopathogenesis of these two condi-
tions and designing future studies.
The main strength of this systematic review is its
methodology, which was carried out in accordance
with PRISMA guidelines [9] with the associated
protocol pre-registered on PROSPERO. Since we an-
ticipated limited published data, we sought advice
from a database searching specialist to ensure our
search syntax was as broad as possible. We hand-
searched the reference lists of excluded review articles
and used expert opinion to ensure key studies in the
field had been captured within our database searches.
All stages of screening, data extraction and risk of
bias assessment involved a second reviewer. The re-
source availability for this review necessitated that
English language limits were placed on our search
strategy, thus it is possible that relevant literature
published in another language was not identified.
However, the literature included in this review sup-
ports the epidemiological data that JIAU is most
common in Europe and North America [32]. Since
our protocol only allowed for inclusion of full text
peer-reviewed articles rather than abstracts/conference
proceedings it is possible that relevant ‘grey literature’
was not included. During full text review, 20/67 stud-
ies were excluded as data was only available as a con-
ference abstract. Six of these had readily identifiable
peer-reviewed manuscripts which were also captured
within our database searches. From the data or co-
horts presented in the remaining 14 conference ab-
stracts it appears possible that a number of these
formed part of a larger dataset which was subse-
quently published however we cannot be certain. It
seems likely that the number of studies that appear
only in the ‘grey literature’ (i.e. not published in peer-
reviewed journal articles) is likely to be small, how-
ever we cannot fully exclude the potential for publica-
tion bias. We restricted our study inclusion to those
studies examining JIA-U incidence and subsequently
limited our data extraction to the same – further
work will be required to evaluate the role of
environmental risk factors in JIA-U disease activity
and/or severity.
Conclusion
Whilst JIA-U is considered a complex disease influenced
by genetics and the environment, this systematic review
identified a very limited number of studies investigating
environmental risk factors and their association with
JIA-U incidence, thus illustrating a paucity of research in
this area. The data available suggest an association be-
tween JIA-U and vitamin D, and JIA-U and allergy/al-
lergy medications however these results must be
interpreted with caution as they represent the output of
single studies. Further studies are needed to strengthen
the evidence of these associations and explore their
contexts.
A co-ordinated and collaborative effort is needed to
identify JIA patient cohorts that not only have sufficient
ophthalmic follow-up data over a prolonged period to
accurately discern JIA-U case status, but that can also
analyse putative patient risk factors whilst accounting
for potential confounding. International partnerships are
likely to be required to generate enough studies to en-
able meta-analysis of supposed JIA-U risk factors.
Undertaking such work to detect JIA patients with
modifiable JIA-U risk factors or identify those who may
be at particularly increased risk compared to the current
accepted JIA-U risk profile would be of considerable
benefit to patients and allow more efficient use of health
resources for screening.
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